Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses the role of DHEA in intracrinology, highlighting its impact on breast and prostate cancer treatment and potential as a menopause therapy, but reports no new research findings.

This article reviews clinical and treatment aspects of hyperandrogenism in women, emphasizing the roles of diagnostic practices, combined oral contraceptives, and cyproterone acetate, but introduces no new findings.

This study found that while 11-oxyandrogens do not aid in diagnosing PCOS, they correlate with hirsutism severity, and 11-ketotestosterone levels decrease with combined oral contraceptive therapy.

This study found that progesterone can increase glycine release in rat brainstem neurons through its conversion to allopregnanolone, which modulates presynaptic GABA receptor activity.

In this study, two different estroprogestin treatments significantly improved skin conditions and decreased androgen levels in hyperandrogenic women, with EE/DRSP showing more pronounced hormonal changes and skin improvements compared to EE/CMA.

This study found that in non-obese women with moderate body hair growth, DHEA-S and prolactin levels were higher, and SBP was lower compared to controls, which may inform treatment decisions.

This article reviews the problem of acne and hirsutism in women, highlighting the effectiveness of combined oral contraceptives containing drospirenone and levomefolate calcium in managing these conditions and polycystic ovary syndrome, but no new clinical results are reported.

Progesterone increases alcohol tolerance and withdrawal anxiety, while DHEAS prevents them.

In this study, pregnenolone was found to dose-dependently reduce L-DOPA-induced dyskinesias in a rat model of Parkinson's disease, suggesting its potential as a therapeutic target for these dyskinesias.

This review discusses the use of ethinylestradiol combined with antiandrogenic progestin for treating androgenisation symptoms and improving metabolic and menstrual health in women, but it does not provide new clinical data.

This study found that a new analytical approach revealed an increased brain pregnenolone level following finasteride treatment in a mouse model, suggesting potential for improved understanding of neurosteroid roles in brain excitability.

This study found that progesterone derivatives with chlorine or bromine substituents were effective in inhibiting 5α-reductase activity in human prostate and exhibited antiandrogenic effects in hamster flank organs.

This study found that progesterone enhances the survival of newborn neurons in the hippocampus of adult male mice, which is associated with improved spatial learning and memory.

This review discusses developments in oral contraceptives, highlighting improved individualization, reduced side effects, and enhanced suitability for various women's health needs, but it reports no new clinical results.

This review found no evidence that DHEA improves quality of life or decreases menopausal symptoms in peri- and postmenopausal women, but it may slightly enhance sexual function compared to placebo.

In this study, cyproterone acetate combined with estradiol dramatically improved hirsutism symptoms and significantly reduced plasma testosterone and androstenedione levels in patients over periods of up to three years.

This article reviews the medical history and symptoms related to hyperandrogenism in patients, but reports no new clinical findings.

This study suggests that the progesterone metabolite allopregnanolone and progesterone regulate distinct gene sets involved in glioblastoma cell proliferation, with some overlapping effects modified by finasteride.

This review examines the role of androgens in cutaneous disorders and the potential therapeutic effects of different oral contraceptives, noting variations in individual responses and the influence of genetic and local factors but reports no new clinical results.

This study suggests that the neurosteroid allopregnanolone may play a crucial role in how ethanol affects neurons related to alcohol addiction vulnerability.

This study found that both combined therapy with goserelin and oral contraceptives, and oral contraceptives alone, significantly reduced hair diameter in severe hirsutism without a significant difference between treatments.

This article discusses the use of oral contraceptives for treating hyperandrogenism in women, reporting improvement in most patients, especially in reducing new hair growth, but presents no new clinical findings.

In this study, oral dienogest combined with ethinylestradiol provided effective contraception with a Pearl Index of approximately 0.2 and improved androgenic symptoms without significant metabolic effects.

This study measured estradiol and progesterone in the scalp hair of pre- and postmenopausal women using immunoassay, but found no statistical significance in hormone concentration differences between the groups.

This study found that medroxyprogesterone injections led to partial or complete hair regrowth in some Pomeranian dogs with alopecia X, though their IGF-1 levels remained unchanged.

This review evaluates therapies for hyperandrogenism, highlighting cyproterone acetate as the preferred treatment due to its potency and tolerability in managing symptoms in women.

This study found that in newborn rats, progesterone's effects on apnoea frequency are influenced by a sex-specific balance between its metabolite allopregnanolone and progesterone receptors.

In this study, cyproterone acetate at 2 mg daily was found to be as effective as higher doses in reducing hair growth for hirsute women over 12 months.

This study discusses the use of oral contraceptives as a treatment for hyperandrogenism, showing improvement in hirsutism and acne for many women and possibly providing metabolic benefits with certain formulations.

This study developed a sensitive HPLC-MS/MS method for determining cyproterone acetate levels in human plasma and found no significant difference in its concentration between two oral formulations in bioequivalence testing.